probiotic and semaglutide Probiotics with Semaglutide: Safety & Biomarker Context – PlexusDx metabolic health Semaglutide + Probiotics: Biomarker Context

There was no significant difference between groups in remission of diabetes at 6 months (L: 9.1%, P: 18.2%, p = 1.00) and 12 months (L:27.3%, C:25.0%, p = 1.00)

Current guidance supports stratified risk assessment based on individual patient factors rather than routine medication cessation

Biochem Biophys Res Commun 324:9297 Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FP, Flatt PR (2006) Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1

Injection Site Reactions: Many GLP-1 medications are administered via subcutaneous injection, which can lead to injection site reactions such as redness, itching, or swelling

Drugs for diabetes: part 3 thiazolidendiones